DRUG USER FEE REVIEW TIMES MAY BE RIPE FOR OVERSIGHT FROM REPUBLICANS: IS FDA STRETCHING DEADLINES?; KESSLER'S MOVE TO CLINTON PUTS FDA IN PRECARIOUS POSITION
Executive Summary
FDA's progress in meeting its drag user fee review goals are a potential lightning rod for an efficiency-espousing, business- oriented Republican Congress.